ClinicalTrials.gg
RecruitingNCT06484985Updated Jan 28, 2026

Study of AXT-1003 in Subjects With Advanced Malignant Tumors.

A Phase 1 interventional study of AXT-1003 in Non-Hodgkin Lymphoma and Advanced Solid Tumor, sponsored by Axter Therapeutics (Beijing) Co., Ltd. Recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Axter Therapeutics (Beijing) Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 195 studies in Lymphoma, Non-Hodgkin with a site in China — 82 open to participants now, 109 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Planned enrollment
70th of 183
78 · median 58
Started
2024
with 17 others
Phase 1
79 of 195
33 open now
Primary completion
2027-03
later than 66 of 108 live
Registered
166th of 195
by date

Among the 195 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 70th largest by planned enrollment of the 183 interventional ones that give a count, is one of 18 that started in 2024, is one of 79 in phase 1, reaches primary completion later than 66 of the 108 other live ones, and was the 166th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

82 of the 195 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

76 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.

Read the detailed description

AXT1003-1102 is a multicenter, open-label, Phase I safety study of AXT-1003 in patients with advanced malignancies. It is designed to observe the safety of AXT-1003 in patients with advanced malignancies, determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), evaluate the pharmacokinetic profile, and explore the preliminary antitumor activity.

03

Conditions studied

  • Non-Hodgkin Lymphoma
  • Advanced Solid Tumor

Keywords

  • AXT-1003
  • EZH2
  • Phase I
  • Advanced malignancies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. For Ia dose escalation part only:

    R/R NHL: Locally histopathological diagnosis of non-Hodgkin lymphoma (R/R NHL), who have progressed or been intolerant after the available standard therapies, or have no access to the standard therapies.

    Advanced solid tumors: Locally histopathological diagnosis of locally advanced unresectable and solid tumors,The above subjects have progressed or been intolerant after the available standard therapies, or have no access to the standard therapies.

    For Ib dose expansion part only: Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL)

  2. (ECOG) performance status scale 0 to 1.
  3. Have a of at least 3 months.
  4. For Ib dose expansion part and not mandatory for Ia dose escalation part: Subjects with R/R NHL must have as defined by Lugano 2014 criteria. Subjects with advanced solid tumors must have measurable or evaluable lesions as defined by 1.1.
  5. Adequate organ and bone marrow functions.
  6. The adequate for prior therapy .
  7. Subjects must use a highly effective method throughout the study and for 3 months after discontinuation of the study drug.
  8. Signed ICF and willing to comply with all the requirements in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of precursor B-cell lymphoblastic leukemia/lymphoma, precursor T-cell lymphoblastic leukemia/lymphoma, precursor NK cell lymphoblastic leukemia/lymphoma. Diagnosis of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL).
  2. Central nervous system infiltration.
  3. Uncontrolled or significant cardiovascular disease.
  4. Major surgery within 4 weeks before the first dose of study drug.
  5. Known or suspected to AXT-1003 or any of the .
  6. Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of AXT-1003.
  7. History of other prior to enrollment; except for subjects with basal cell carcinoma of skin, squamous cell carcinoma of skin, cervical carcinoma in situ, or other carcinomas in situ who have undergone possible curative treatment and do not have disease recurrence within 5 years since starting the treatment.
  8. Any prior treatment-related toxicities that have not resolved to Grade ≤ 1 or prior treatment-related toxicities that are clinically unstable and clinically significant at time of enrollment.
  9. Active infection requiring systemic treatment.
  10. Infection with virus with positive hepatitis B surface antigen, or virus with detectable anti-hepatitis C circulating viral RNA.
  11. Subjects known to be infected with and active tuberculosis.
  12. Females who are pregnant or breastfeeding.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    AXT-1003

    Dose Escalation: Part A: Level 1 (Starting Dose) Oral AXT-1003 5 mg BID; Level 2 Oral AXT-1003 10mg BID; Level 3 Oral AXT-1003 15mg BID ; Level 4 Oral AXT-1003 20mg BID; Level 5 Oral AXT-1003 25mg BID; Level 6 Oral AXT-1003 30mg BID; Level 7 Oral AXT-1003 35mg BID; Level 8 Oral AXT-1003 40mg BID; Dose Escalation: Part B: Oral AXT-1003 2.5mg QD, 10mg BID; Dose Expansion: 1 or 2 cohorts at the dose levels selected from dose escalation part

    Drug: AXT-1003

Interventions

  • AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicity (DLT) (Dose Escalation)

    Dose Escalation only: to characterize the dose limiting toxicities (DLTs) of AXT-1003.

    Time frame: Up to 28 days

  2. Number of Participants with Adverse Events (AEs)

    Laboratory test ,ECG, vital signs, physical examination

    Time frame: Baseline up to 30 days after the last dose of study

Secondary outcomes

  1. Overall response rates (ORR)

    ORR is defined as the proportion of subjects with a CR or PR.

    Time frame: Up to 3 years

  2. Duration of response(DOR)

    DOR is defined as the time from the initial objective response to progression of disease (PD) or death after the response, whichever occurs first.

    Time frame: Up to 3 years

  3. Progression free survival (PFS)

    Progression-free survival is defined as the time from the first dose of study treatment to the first PD or death for any reason in the absence of documented PD, whichever occurs first.

    Time frame: Up to 3 years

  4. Time to response (TTR)

    Time to response is defined as the time from first dose of study treatment to the first objective tumor response.

    Time frame: Up to 3 years

  5. Disease control rate (DCR)

    Disease control rate is defined as the proportion of subjects with a CR, PR, or stable disease(SD).

    Time frame: Up to 3 years

  6. Maximum observed concentration (Cmax) of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 15 days

  7. Time of maximum observed concentration (tmax) of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 15 days

  8. Area under the curve from the time of dosing to the time of the last measurable concentration (AUCtau) of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 15 days

  9. Minimum observed concentration (Cmin) of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 15 days

  10. Terminal elimination half-life (t1/2) of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 15 days

  11. Total body clearance (CL/F) of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 15 days

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Mar 2027, 30 months after the start.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 30 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2024
First posted
Jul 3, 2024
StartActual
Sep 4, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06484985
Lead sponsor
Axter Therapeutics (Beijing) Co., Ltd
Responsible party
Sponsor
First posted
Jul 3, 2024
Start date
Sep 4, 2024
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jan 28, 2026

Study contacts

Wilson Wang
Contact
wilson.wang@axtertx.com
+86 10 65120010
Qian Gao
study director · Axter Therapeutics (Beijing) Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AXT-1003

Start the discussion